Reata Pharma (RETA) Tops Q1 EPS by 82c

Reata Pharma (NASDAQ: RETA) reported Q1 EPS of ($1.33), $0.82 better than the analyst estimate of ($2.15). Revenue for the quarter came in at $910 thousand versus the consensus estimate of $1.55 million.

For earnings history and earnings-related data on Reata Pharma (RETA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• SanDisk upgraded at JPMorgan after investor day; shares climb